Company Overview
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -66.55% |
| 6 Months: | -50.23% |
| 3 Months: | -44.40% |
| 1 Month: | -16.38% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)44.50 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 69.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NRSN NeuroSense Therapeutics Ltd. PHARMA | 0.42 | -0.05 | $796.70K | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 |
|---|---|
| Revenue | 0 |
| Cost of Revenue | - |
| Gross Profit | - |
| Operating Expenses | 1.77M |
| Operating Income | -1.77M |
| EBITDA | -1.77M |
| Interest Expense | - |
| Pretax Income | -1.80M |
| Tax Provision | - |
| Net Income | -1.80M |
| Diluted EPS | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 10.55M | 12.05M | 9.90M | 11.09M |
| Operating Income | - | -10.55M | -12.05M | -9.90M | -11.09M |
| EBITDA | - | -10.54M | -12.03M | -9.88M | -11.07M |
| Interest Expense | 0 | 15.00K | 11.00K | - | - |
| Pretax Income | - | -10.49M | -10.11M | -10.21M | -11.12M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -10.49M | -10.11M | -10.21M | -11.12M |
| Diluted EPS | - | -0.91 | -0.74 | -0.54 | -0.44 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 7.71M | 3.19M | 4.58M | 1.03M |
| Current Assets | - | 7.38M | 2.92M | 4.40M | 778.00K |
| Cash & Equivalents | - | 3.54M | 2.64M | 3.38M | 166.00K |
| Inventory | - | - | - | - | - |
| Receivables | - | 131.00K | 166.00K | 164.00K | 33.00K |
| Total Liabilities | - | 2.09M | 4.94M | 1.99M | 2.59M |
| Current Liabilities | - | 1.73M | 3.46M | 1.99M | 2.52M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 211.00K | 142.00K | 73.00K | 170.00K |
| Total Equity | - | 5.62M | -1.76M | 2.58M | -1.56M |
| Shares Outstanding | - | 11.78M | 15.38M | 23.23M | 32.56M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -7.62M | -8.35M | -10.13M | -7.67M |
| Investing Cash Flow | - | -3.59M | 3.47M | 1.00K | -8.00K |
| Financing Cash Flow | - | 3.77M | 3.98M | 10.91M | 4.43M |
| Capital Expenditure | - | -70.00K | -29.00K | -3.00K | -8.00K |
| Free Cash Flow | - | -7.69M | -8.38M | -10.14M | -7.68M |
| Net Change in Cash | - | -7.43M | -911.00K | 779.00K | -3.25M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | -186.7% | 574.6% | -395.3% | 713.1% |
| ROCE % | - | -176.4% | 4,397.4% | -383.4% | 745.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | UBS Group AG | 0.29% | 5.43K | $34.49K |
| 2 | Independent Advisor Alliance | 0.26% | 5.00K | $31.75K |
| 3 | Yorkville Advisors Global, LP | 0.21% | 3.90K | $24.76K |
| 4 | Commonwealth Equity Services, LLC | 0.06% | 1.14K | $7.23K |
| 5 | PNC Financial Services Group, Inc. | 0.06% | 1.06K | $6.72K |
| 6 | Pathstone Holdings, LLC | 0.04% | 826 | $5.25K |
| 7 | Geode Capital Management, LLC | 0.04% | 794 | $5.04K |
| 8 | Xtx Topco Ltd | 0.03% | 574 | $3.64K |
| 9 | Creative Planning | 0.03% | 571 | $3.62K |
| 10 | HRT Financial LP | 0.03% | 526 | $3.34K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NRSN
Neurosense Therapeutics Stock Price Forecast. Should You Buy NRSN? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE5SQ3Q2OXBTdEhYclNlZjg5blNEWGdjcGY4cUhRc09MLWthR1JzZkhBYW12WmtmR0NWTnY1V3Z0c0hxM0FSb2ZkVQ?oc=5" target="_blank">Neurosense Therapeutics Stock Price Forecast. Should You Buy NRSN?</a…
$NRSN stock is up 19% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOR2g1YVpjVmdZeGdLaFY5UnNmbjNob3d6My1PTWtMYzZKVU8tZWEwSjM4Nkx4WjFOV3BLX2RlUW14TE5MVU00VDBxTkNXRkNLM0dtN3JvbWlMemhWS0dUVUI2Q29NRkppYVVCZVYteFBRWG1JYUdWZEdLZjBjNi1KU25USFZCQm1IWk1uMk…
NeuroSense Seeks Funding for ALS Trial Expected to Enroll ~300 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxNX2JKeTAyYW51MGlidF9JeW9xZk10QmNnUktwZ0NObGZFM1hTX2djU2hDVW9aOGx5dTJ3Y2VwSzNLY3pzb1B0M255X3M4LWZKeVlENGlDNmVxSU5XaUVyQjdwMjZlVVR5WG0yWXhCbVB0MEdCRTdjbXY5UlByVHdhRTZOaWIwOU5pbHBIaz…
NeuroSense Therapeutics Ltd. Revenue Breakdown – NASDAQ:NRSN - tradingview.com
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTFB0bldkVGtBWndhTWplMHgzZi1YaGlycXJ0YXlwejNUSjNJVmVvdVhoX084a0ZuRTNPOGMtc1dvQ1lMTDR2TTRMVmItY0N0UktYcHZlTXltOHp3U3pBWDRITW9wUDY2SXpLekpHQ284dmdmOVVTWFBr?oc=5" target="_blank">NeuroSe…
NRSN - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE5WdEZCa1BIZDdvZUdZdURCSkcweUJSSVZwc1V5UmZTSFZ6ZnIxMzYzb25ZSGxPR1lKSXI2S1ZkUlIzdDJWbGc?oc=5" target="_blank">NRSN</a> <font color="#6f6f6f">Finviz</font>…
Why Is NeuroSense (NASDAQ:NRSN) in Focus Before Tuesday’s Open? - Kalkine Media
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOYzJ4WU0yTFhfZ0JZMkpWa1ZqazJBWlZyU3h6ZzJUNXdzZ1p5VDFUUTlrMXJsZDQ2anlZek5jeFR6aTJfSjJ1YWZqVEdTeTM0MW1zb3dZM3g5Zl9lOGxNd2lkOTNodThOZXJaOEUwRFFadWNBTGdLX3ZBVDRCYTBKVHRPeC1McjlaYktZR2…
NRSN — Frequently Asked Questions
What is the current share price of NeuroSense Therapeutics Ltd. (NRSN)?
As of 2026-09-19 21:16 PDT, NeuroSense Therapeutics Ltd. (NRSN) trades at $0.42 on NasdaqCM. Its 52-week range is $0.35 to $1.36.
What is the market capitalisation of NRSN?
NeuroSense Therapeutics Ltd. (NRSN) has a market capitalisation of $796.70K on NasdaqCM.
What is the P/E ratio of NRSN?
NRSN trades at a trailing price-to-earnings (P/E) ratio of -0.05. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -6.63.
Is NRSN a good stock to buy?
This page provides a data-driven analysis of NeuroSense Therapeutics Ltd. (NRSN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.